Hepatitis B in China

Last updated

Hepatitis B is endemic in China . [1] Of the 350 million individuals worldwide infected with the hepatitis B virus (HBV), one-third reside in China. [2] As of 2006 China has immunized 11.1 million children in its poorest provinces as part of several programs initiated by the Chinese government and as part of the Global Alliance for Vaccines and Immunization (GAVI). However, the effects of these programs have yet to reach levels of immunization that would limit the spread of hepatitis B effectively.

Contents

Epidemiology

Prevalence

Of the 350 million to 400 million individuals worldwide infected with the hepatitis B virus (HBV), one-third reside in China, with 130 million carriers and 30 million chronically infected. [2] [3] Since the Expanded Program on Immunization (EPI) beginning 1992, the prevalence of HBV has declined, especially among children 3 to 12 years old. [4] [5] During a 5-year period, 10.0% of patients with chronic hepatitis developed cirrhosis, and 20.3% of the cases with compensated cirrhosis progressed to decompensated cirrhosis. 6.5% of the people with cirrhosis and chronic hepatitis progressed to hepatocellular carcinoma (HCC). 5-year survival for compensated cirrhosis is 55%, that for decompensated cirrhosis is 14%, and that for HCC is less than 5%. [6] Every year, 300,000 people die from HBV-related diseases in China, including 180,000 patients with HCC. [7] However, the incidence of hepatitis B is still increasing, from 21.9 in 100,000 people in 1990 to 53.3 in 100,000 in 2003. [8] That increase has occurred despite a vaccination program for newborn babies since the 1990s, which showed good effectiveness for reducing chronic HBV infection in children. [9]

Transmission

The reason for this increased HBV infection is unknown, because hepatitis B has no clear transmission routes in many people in China, although both neonatal infection and horizontal transmission during early childhood are still the most common routes. During and before the Cultural revolution many of the cases came from re-used needles that were contaminated with HBV.

Programs

Public awareness

Public awareness of the disease, which is spread through the exchange of bodily fluids, is not as high as it is for HIV and AIDS. In some rural areas, doctors have reused syringes and unknowingly spread the disease, particularly among children.

Vaccination

By 2006, China has successfully immunised 11.1 million children living in the country's poorest provinces against hepatitis B according to the Chinese health ministry, and the Global Alliance for Vaccines and Immunization (GAVI). However, China still has a long way to go before immunisation levels reach a percentage able to limit the spread of hepatitis B. China's health minister, Gao Qiang told a Beijing press conference that the project, while effective, has covered only one third of all children born in China since the project began in 2002. This does not mean the rest of China's children went unvaccinated. However, even within the project's target area, over one million newborns went unvaccinated each year because of access issues; health-care costs, lack of birth attendants, and the remoteness of their birthplaces, such as herder's huts, mountain villages, and remote farms.

Until 2005, when a law banning the practice was passed, parents were charged fees for the administration of the vaccine. Even though the GAVI alliance (whose partners include UNICEF and the WHO), and Chinese government were providing the vaccine and one-use needles free of charge, health-care workers charged fees that parents were unwilling or unable to pay.

Based on a 1992 epidemiological survey, the disease burden of those who are chronically infected with hepatitis B in China is estimated to be at 120 million, one third of the overall burden (360 million) as estimated by the WHO.

China's national target is to reach greater than 85% vaccination. The joint project with the GAVI alliance has shown that this is feasible with three quarters of the 1301 project counties reporting that 85% or more children received three doses of HepB vaccine. In hospitals designated as project hospitals, the percentage of newborns vaccinated within 24 hours of birth is now over 90%. However, the overall newborn vaccination rate in the region covered by the GAVI alliance/government joint project was 70%, lower than the 75% they hoped to achieve.

Achieving long-term success will require "assuring no new financial barriers arise", said Julian Lob-Levyt, Executive Secretary of the GAVI Alliance. "This is one of the greatest challenges and the solution lies not just within China but with a global community mobilized to ensure access to vaccine financing for all developing nations."

Home to a large population of ethnic minorities of low socioeconomic status, the Qinghai province is a remote, often neglected, rural region of China with a high prevalence of chronic hepatitis B. Since many children 5 years of age and older in Qinghai were not vaccinated against the hepatitis B virus at birth, a private-public partnership was formed between the Ping and Amy Chao Foundation, the ZeShan Foundation, the Asian Liver Center at Stanford University, the China Center for Disease Control and Prevention, the Chinese Foundation for Hepatitis Prevention and Control, and the Qinghai government. Using the existing provincial China CDC structure, this private-public partnership in Qinghai resulted in a unique two-part school-based immunization program to educate and provide free Hep B vaccination for all children in kindergarten and grade school within the region. [10] [11]

Between 2006 and 2008, this program demonstrated the feasibility and successful implementation of:

  1. A province-wide catch-up vaccination program that reached 600,000 children in 2,200 schools, and
  2. A hepatitis B education program incorporated into the school curriculum.

Impact: The success of this large scale province-wide demonstration program led the Chinese government to announce the adoption of a new policy beginning in 2009 to provide free catch-up hepatitis B vaccination for all children in China under the age of 15 who have not been vaccinated.

Treatment

Because a high load of HBV in patients is the main cause of hepatitis progression, the ultimate goal in treatment is to eradicate the virus before irreversible liver damage occurs. [12]

Unfortunately, there are no agents available with high enough efficacy and safety to fully eradicate HBV. Neither interferon alpha, including standard and pegylated forms, nor nucleotide analogues (including lamivudine, adefovir dipivoxil, and most recently, entecavir) could eradicate HBV covalently-closed-circular DNA in liver cells, which is the replication model for HBV recurrence. However, no agents are available to break through the host's immune tolerance to HBV, which is another important reason for persistent infection with HBV, [13] although some patients respond well temporarily to administration of interferon and nucleotide analogues alone or in combination regimens. [14] Some traditional Chinese herbs, such as kushenin ( Sophora flavescens ) and some complex prescriptions, have some efficacy as antivirals and in the protection of liver function, although the specific mechanism and components need to be identified. The current treatment in China is the combination of antiviral agents (lamivudine, adefovir dipivoxil), immune modulators (interferon alpha, peginterferon alpha, thymosin), and hepatic protectors (such as glycyrrhizin, glucuronolactone). The Chinese spend around ¥900 billion (US$110 billion) on these regimens every year. [15] Apart from cost, patients and carriers of HBV infection are often confronted with tough conditions and social pressures, although such discrimination is illegal in China.

Chinese drug regulation authorities have approved Swiss pharmaceutical firm Novartis AG's drug Sebivo, a brand name for telbivudine, as a treatment for chronic hepatitis B in February 2007. The decision comes shortly after Sebivo was recommended for approval in the European Union. The medicine was developed jointly by Novartis and U.S. biotech firm Idenix Pharmaceuticals Inc and has been shown in trials to produce significantly greater viral suppression compared to the commonly used treatment lamivudine. Sebivo won its first major approval in Switzerland in September 2006.

Governmental intervention

Problems

There have been relatively few campaigns aimed at ending the practice of reusing needles. For standard preventative practice, a vaccination within the first 24 hours after birth is considered the best way to prevent the disease from spreading from mother to child. But it was not until 1992 that China included it as part of a routine immunization program. Even then, the price was relatively high compared with other postnatal vaccinations, and families had to pay for it privately. Many have suffered and their families, especially in the poor countryside, decided to go without.

According to China's Ministry of Health website, in 2005 the PRC government belatedly passed a regulation making the vaccination free. The PRC government has set a goal of reducing the overall hepatitis B infection rate to less than 7% over the next five years, and the rate of infection for children younger than 5 to less than 1%. It has been said by medical observers of prevention programs in the country that the program can be a viable model for other developing countries trying to stop the spread of diseases (including hepatitis B) that can be prevented by vaccines. But a study of some campaigns shows that more than 1 million Chinese babies born each year in the area covered by the government initiated programs are not receiving the vaccination. Officials involved in the hepatitis B vaccination programs say that in many of China's poverty-stricken rural areas, children are delivered at home in remote mountain villages or nomadic herders' tents, far from hospitals and access to medical information. The Chinese Center for Disease Control and Prevention (China CDC) have conducted research that supports the evidence that "there was and is still a huge bottleneck to ensure the delivery of the timely birth dosage to home births".

Another problem is the growing size of China's migrant labor force or "floating population." Farmers or peasants who become urban laborers move frequently around the country and often do not seek medical attention. The immunization rate among them remains low, said China CDC. One major problem facing Chinese people infected with hepatitis B is that illegal blood testing is required by most employers in China. Anyone that tests positive for hepatitis B is either denied employment or fired. Laws do exist to protect the privacy of employees and job seekers but they are not enforced.

Research

Hepatitis B and its related disorders are important public health issues in China, which not only presents challenges for doctors and scientists but also increases the burden for the government. Last year, the Chinese Government funded research with around Ɲ3 billion (US$390 million), mainly against hepatitis B and related diseases over the next decade. [16] [17]

Research will include: large retrospective and prospective studies of the population vaccinated against hepatitis B and the incidence of HCC; genetic variation in HBV and its subtypes, and mutations in HBV DNA in the response to interferon and nucleotide analogues; host-gene variation and the therapeutic response, including single-nuclear polymorphisms and gene copy-number variations; virus mutation and the mechanism of the immune response in fulminant liver failure, and the immunological factors which cause liver injury and the markers which predict reduction in liver function; assessment and prediction of liver fibrosis by non-invasive biomarkers, and interference with fibrosis from small chemical compounds or traditional Chinese medicines; prediction of the development, metastasis, and prognosis of HCC by molecular typing; and the identification of important signal transduction pathways in HCC and the development of new small chemical compounds to target HCC.

Progress

To measure the results, the Government also set goals that corresponded to these research projects. The goals include: completion of the immunoprophylaxis strategy, such as HBV vaccine, to decrease the incidence of HCC by more than 10%; identification of molecular biomarkers, and the creation of molecular-typing diagnostic kits for the prediction of the therapeutic response; the development of regimens to treat HBV; the identification of biomarkers to predict the aggressiveness of severe hepatitis B and the development of a kit for early diagnosis of liver cirrhosis; the identification of markers (biological and genomic, and small molecules) for early diagnosis and to predict recurrence and metastasis, and the development of new drugs for HCC, to increase the rate of early diagnosis by more than 20% and 5-year survival by more than 5%. The fight against HBV and its related disorders is now thought of as a long-term one by the health authorities.

Social impact

Discrimination

People with Hepatitis B in China frequently face discrimination in all aspects of life and work. For example, many Chinese employers and universities refuse to accept anyone who tests positive. Some kindergartens refuse admission to children who are carriers of the virus. The hepatitis problem is a reflection of the vast developmental gap between China's rural and urban areas. The largest problem facing Chinese people infected with HBV is that illegal blood testing is required by most employers in China. [18] According to a report by PBS, faking blood tests by hiring uninfected individuals to take them has become widespread. [19] Following an incident involving a Hepatitis B carrier's killing of an employer and other calls against discriminatory employment practices, China's ministries of health and personnel announced that Hepatitis B carriers must not be discriminated against when seeking employment and education.[ citation needed ] While the laws exist to protect the privacy of employees and job seekers, many believe that they are not enforced.

"In the Hepatitis B Camp"

"In the Hepatitis B Camp" is a popular website for hepatitis B carriers' human rights in China. Its online forum is the world's biggest such forum with over 300,000 members. The website was first shut down by the Chinese government in November 2007. Lu Jun, the head of the rights group, managed to reopen the website by moving it to an overseas server, but the authorities in May 2008 began blocking access to the website within China, only 10 days after government officials participated in an event for World Hepatitis Day at the Great Wall of China. An official had told the head of the rights group, Lu Jun, at the time that the closure was due to the Beijing Olympic Games. [20]

See also

Related Research Articles

<span class="mw-page-title-main">Hepatitis</span> Inflammation of the liver

Hepatitis is inflammation of the liver tissue. Some people or animals with hepatitis have no symptoms, whereas others develop yellow discoloration of the skin and whites of the eyes (jaundice), poor appetite, vomiting, tiredness, abdominal pain, and diarrhea. Hepatitis is acute if it resolves within six months, and chronic if it lasts longer than six months. Acute hepatitis can resolve on its own, progress to chronic hepatitis, or (rarely) result in acute liver failure. Chronic hepatitis may progress to scarring of the liver (cirrhosis), liver failure, and liver cancer.

<span class="mw-page-title-main">Hepatitis C</span> Human viral infection

Hepatitis C is an infectious disease caused by the hepatitis C virus (HCV) that primarily affects the liver; it is a type of viral hepatitis. During the initial infection period, people often have mild or no symptoms. Early symptoms can include fever, dark urine, abdominal pain, and yellow tinged skin. The virus persists in the liver, becoming chronic, in about 70% of those initially infected. Early on, chronic infection typically has no symptoms. Over many years however, it often leads to liver disease and occasionally cirrhosis. In some cases, those with cirrhosis will develop serious complications such as liver failure, liver cancer, or dilated blood vessels in the esophagus and stomach.

Hepatitis D is a type of viral hepatitis caused by the hepatitis delta virus (HDV). HDV is one of five known hepatitis viruses: A, B, C, D, and E. HDV is considered to be a satellite because it can propagate only in the presence of the hepatitis B virus (HBV). Transmission of HDV can occur either via simultaneous infection with HBV (coinfection) or superimposed on chronic hepatitis B or hepatitis B carrier state (superinfection).

<span class="mw-page-title-main">Hepatocellular carcinoma</span> Medical condition

Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer in adults and is currently the most common cause of death in people with cirrhosis. HCC is the third leading cause of cancer-related deaths worldwide.

<span class="mw-page-title-main">Viral hepatitis</span> Liver inflammation from a viral infection

Viral hepatitis is liver inflammation due to a viral infection. It may present in acute form as a recent infection with relatively rapid onset, or in chronic form, typically progressing from a long-lasting asymptomatic condition up to a decompensated hepatic disease and hepatocellular carcinoma (HCC).

<span class="mw-page-title-main">Lamivudine</span> Chemical compound

Lamivudine, commonly called 3TC, is an antiretroviral medication used to prevent and treat HIV/AIDS. It is also used to treat chronic hepatitis B when other options are not possible. It is effective against both HIV-1 and HIV-2. It is typically used in combination with other antiretrovirals such as zidovudine, dolutegravir, and abacavir. Lamivudine may be included as part of post-exposure prevention in those who have been potentially exposed to HIV. Lamivudine is taken by mouth as a liquid or tablet.

<span class="mw-page-title-main">Jade Ribbon Campaign</span> Asian Liver Center campaign

The Jade Ribbon Campaign (JRC) also known as JoinJade, was launched by the Asian Liver Center (ALC) at Stanford University in May 2001 during Asian Pacific American Heritage Month to help spread awareness internationally about hepatitis B (HBV) and liver cancer in Asian and Pacific Islander (API) communities.

<span class="mw-page-title-main">Liver cancer</span> Medical condition

Liver cancer, also known as hepatic cancer, primary hepatic cancer, or primary hepatic malignancy, is cancer that starts in the liver. Liver cancer can be primary in which the cancer starts in the liver, or it can be liver metastasis, or secondary, in which the cancer spreads from elsewhere in the body to the liver. Liver metastasis is the more common of the two liver cancers. Instances of liver cancer are increasing globally.

<span class="mw-page-title-main">Hepatitis B vaccine</span> Vaccine against hepatitis B

Hepatitis B vaccine is a vaccine that prevents hepatitis B. The first dose is recommended within 24 hours of birth with either two or three more doses given after that. This includes those with poor immune function such as from HIV/AIDS and those born premature. It is also recommended that health-care workers be vaccinated. In healthy people, routine immunization results in more than 95% of people being protected.

<span class="mw-page-title-main">Hepatitis B</span> Human viral infection

Hepatitis B is an infectious disease caused by the hepatitis B virus (HBV) that affects the liver; it is a type of viral hepatitis. It can cause both acute and chronic infection.

<span class="mw-page-title-main">Yellow fever vaccine</span> Vaccine that protects against yellow fever

Yellow fever vaccine is a vaccine that protects against yellow fever. Yellow fever is a viral infection that occurs in Africa and South America. Most people begin to develop immunity within ten days of vaccination and 99% are protected within one month, and this appears to be lifelong. The vaccine can be used to control outbreaks of disease. It is given either by injection into a muscle or just under the skin.

<span class="mw-page-title-main">2009 Gujarat hepatitis outbreak</span> Disease outbreak in India

The 2009 Gujarat hepatitis B outbreak was a cluster of hepatitis B cases that appeared in Modasa, northern Gujarat, India in 2009. Over 125 people were infected and up to 49 people died. Several doctors were investigated and arrested after the outbreaks.

<i>Hepatitis B virus</i> Species of the genus Orthohepadnavirus

Hepatitis B virus (HBV) is a partially double-stranded DNA virus, a species of the genus Orthohepadnavirus and a member of the Hepadnaviridae family of viruses. This virus causes the disease hepatitis B.

cccDNA is a special DNA structure that arises during the propagation of some viruses in the cell nucleus and may remain permanently there. It is a double-stranded DNA that originates in a linear form that is ligated by means of DNA ligase to a covalently closed ring. In most cases, transcription of viral DNA can occur from the circular form only. The cccDNA of viruses is also known as episomal DNA or occasionally as a minichromosome.

The Asian Liver Center is a non-profit organization at Stanford University, United States, that researches the high incidence of hepatitis B and liver cancer in Asians and Asian Americans. The Asian Liver Center (ALC) was founded in 1996 to spearhead educational outreach and advocacy efforts in the areas of hepatitis B and liver cancer prevention and treatment, serves as a resource for both the general public and health practitioners, and implements clinical and research programs.

The transmission of hepadnaviruses between their natural hosts, humans, non-human primates, and birds, including intra-species host transmission and cross-species transmission, is a topic of study in virology.

Robert Palmer Beasley was an American physician, public health educator and epidemiologist whose work on hepatitis B involved extensive investigations in Taiwan. That work established that hepatitis B virus (HBV) is a primary cause of liver cancer and that hepatitis B virus is transmitted from mother to infant during childbirth. Beasley and his colleagues also proved that HBV mother-to-infant transmission is preventable by at-birth vaccination. Due to this work, the World Health Assembly designated HBV as the seventh global vaccine in 1992. He later became the author of HBV immunization policies for the World Health Organization.

<i>Woolly monkey hepatitis B virus</i> Species of virus

The woolly monkey hepatitis B virus (WMHBV) is a viral species of the Orthohepadnavirus genus of the Hepadnaviridae family. Its natural host is the woolly monkey (Lagothrix), an inhabitant of South America categorized as a New World primate. WMHBV, like other hepatitis viruses, infects the hepatocytes, or liver cells, of its host organism. It can cause hepatitis, liver necrosis, cirrhosis, and hepatocellular carcinoma. Because nearly all species of Lagothrix are threatened or endangered, researching and developing a vaccine and/or treatment for WMHBV is important for the protection of the whole woolly monkey genus.

<span class="mw-page-title-main">Epidemiology of hepatitis D</span> Instance, distribution, and control of Hepatitis D

The epidemiology of hepatitis D occurs worldwide. Although the figures are disputed, a recent systematic review suggests that up to 60 million individuals could be infected. The major victims are the carriers of the hepatitis B surface antigen (HBsAg), who become superinfected by the HDV, and intravenous drug users who are the group at highest risk. The infection usually results in liver damage ; this is most often a chronic and severe hepatitis rapidly conducive to cirrhosis.

George Lau is a specialist in gastroenterology and hepatology, currently the founder and chairman of the Humanity and Health Medical Group in Hong Kong.

References

  1. ↑ "Hepatitis B Surveillance and control". World Health Organization. Archived from the original on 2009-12-03. Retrieved 2009-10-23.
  2. 1 2 Custer B, Sullivan SD, Hazlet TK, Iloeje U, Veenstra DL, Kowdley KV (2004). "Global epidemiology of hepatitis B virus". J. Clin. Gastroenterol. 38 (10 Suppl 3): S158–68. doi:10.1097/00004836-200411003-00008. PMID   15602165. S2CID   39206739.
  3. ↑ Liu, J.; Fan, D. (2007). "Hepatitis B in China". The Lancet. 369 (9573): 1582–1583. doi:10.1016/S0140-6736(07)60723-5. PMID   17499584. S2CID   27720470.
  4. ↑ Liang, X. F.; Chen, Y. S.; Wang, X. J.; He, X.; Chen, L. J.; Wang, J.; Lin, C. Y.; Bai, H. Q.; Yan, J.; Cui, G.; Yu, J. J. (2005). "A study on the sero-epidemiology of hepatitis B in Chinese population aged over 3-years old". Zhonghua Liu Xing Bing Xue Za Zhi = Zhonghua Liuxingbingxue Zazhi. 26 (9): 655–658. PMID   16471211.
  5. ↑ Sun, Z.; Ming, L.; Zhu, X.; Lu, J. (2002). "Prevention and control of hepatitis B in China". Journal of Medical Virology. 67 (3): 447–450. doi: 10.1002/jmv.10094 . PMID   12116043. S2CID   25875631.
  6. ↑ Si, CW (2006). "Current status and problem of chronic hepatitis B". Clin Med J (in Chinese). 4 (4): 1–2.
  7. ↑ Jia; Zhuang, H. (2004). "The overview of the seminar on chronic hepatitis B". Zhonghua Gan Zang Bing Za Zhi = Zhonghua Ganzangbing Zazhi = Chinese Journal of Hepatology. 12 (11): 698–699. PMID   15623388.
  8. ↑ Wang, XJ; Zhang, RZ; Hu, YS; Liang, XF (2004). "Analysis on epidemic status of viral hepatitis in China". Disease Surveillance (in Chinese) (19): 290–293. doi:10.3784/j.issn.1003-9961.2004.8.290 (inactive 2024-09-12). ISSN   1003-9961. Archived from the original on 10 June 2015. Retrieved 2 June 2013.{{cite journal}}: CS1 maint: DOI inactive as of September 2024 (link)
  9. ↑ Cui, FQ; Wang, XJ; Laing, XF (Nov 2006). "Epidemiological Analysis on Reported Hepatitis B Under 15 Years in China". China's Immunization (in Chinese). 12 (3). ISSN   1006-916X. Archived from the original on 2015-06-10. Retrieved 2013-06-02.
  10. ↑ Chen Jonathan J (2012-06-01). "A model program for hepatitis B vaccination and education of schoolchildren in rural China". International Journal of Public Health. 57 (3): 581–588. doi:10.1007/s00038-011-0289-x. PMID   21845405. S2CID   9637008.
  11. ↑ "Safety Shot: Three Young Americans stop at nothing to halt one of Asia's Biggest Killers". Stanford School of Medicine. 2008-04-01. Retrieved 2017-03-01.
  12. ↑ Sung, J. J.; Wong, M. L.; Bowden, S.; Liew, C. T.; Hui, A. Y.; Wong, V. W.; Leung, N. W.; Locarnini, S.; Chan, H. L. (2005). "Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy". Gastroenterology. 128 (7): 1890–1897. doi: 10.1053/j.gastro.2005.03.009 . PMID   15940624.
  13. ↑ Lok, A. S. -F. (2005). "The Maze of Treatments for Hepatitis B". New England Journal of Medicine. 352 (26): 2743–2746. doi:10.1056/NEJMe058119. PMID   15987924. S2CID   19796106.
  14. ↑ Janssen, H.; Van Zonneveld, M.; Senturk, H.; Zeuzem, S.; Akarca, U.; Cakaloglu, Y.; Simon, C.; So, T.; Gerken, G.; De Man, R. A.; Niesters, H. G.; Zondervan, P.; Hansen, B.; Schalm, S. W. (2005). "Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial". The Lancet. 365 (9454): 123–129. doi:10.1016/S0140-6736(05)17701-0. PMID   15639293. S2CID   21294435.
  15. ↑ Zhuang, H (2005). "The challenge of hepatitis B infection in China". Chin J Infect Dis (in Chinese) (23): 2–6.
  16. ↑ "The People's Republic of China Ministry of Science and Technology" (in Chinese). Beijing, China: Chinese government. Retrieved 2009-10-23.
  17. ↑ "National Natural Science Foundation of China". Chinese government. Archived from the original on 2010-01-10. Retrieved 2009-10-23.
  18. ↑ "Hep B carriers allowed to join public service". China Daily. 21 May 2005. Retrieved 2 June 2013.
  19. ↑ Faking Blood Tests to Avoid Discrimination in China Archived 2014-01-22 at the Wayback Machine . newshours.pbs.org. Accessed 2011-10-06.
  20. ↑ Kwong, Robin (2008-06-25). "Group warns China on website shutdown". Hong Kong: Financial Times. Retrieved 2009-10-23.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.